universe ddl blog

AtCor Medical (ASX: ACG),
the developer and marketer of the SphygmoCor(R) system, which
measures central blood pressures and arterial stiffness
noninvasively, today responded to media reports on a study* available
online in the American Journal of Physiology, published by the
American Physiological Society.
The University of Illinois at Urbana-Champaign study compared
vascular function in groups of healthy young African American and
Caucasian men. The study found that while both groups of men had
similar brachial cuff (measured at the arm) blood pressures, the
young African American men had high central blood pressures (the
pressure in the ascending aorta). Elevated central blood pressure,
which cannot be detected with traditional cuff blood pressure
measurement, is associated with increased risk of heart attack,
stroke and kidney disease. AtCor Medical’s SphygmoCor technology
was used to noninvasively measure central blood pressure during the
study.
The University of Illinois study highlights the limitations of using
standard cuff blood pressure measurement alone in diagnosing and
treating hypertension. "Our results support the notion that brachial
BP (blood pressure) does not reflect vascular burden, particularly in
young healthy African American men and alterations in central
pressure may precede alterations in brachial pressure," the authors
stated.
Elevated Central Pressure: Elevated Risk of Heart Attack, Stroke,
Kidney Disease
The adverse implications of elevated central blood pressure have been
observed in a number of other studies. The Strong Heart Study,
funded by the National Institutes of Health (NIH), involving over
3,500 patients, showed in a multivariate analysis that central blood
pressure, measured with SphygmoCor, but not brachial blood pressure,
predicted cardiovascular events. A follow-on analysis of Strong
Heart Study data, recently presented at the American Heart
Association Scientific Sessions 2008, defined a specific level of
central pulse pressure (50mmHg) above which adverse cardiovascular
events increase significantly. That study’s authors called for
consideration of central pulse pressure as a treatment target in
clinical intervention strategies.
"It is well recognized that African American men have a higher
prevalence of hypertension," said Duncan Ross, AtCor President and
CEO. "Detecting elevated central pressure early — allowing timely
intervention — may help prevent cardiovascular disease in later
life. As the U of I study authors observed, the measurement of
central blood pressure may fill a crucial void in the current
management of hypertension. Yet again, the science shows that it is
critically important to measure central blood pressure," Ross
concluded.
About AtCor Medical
AtCor Medical develops and markets products for the early detection
of cardiovascular risk and management of cardiovascular disease. Its
technology allows researchers and clinicians to measure central blood
pressure noninvasively. The company’s SphygmoCor system visibly
identifies the effects of reflected blood pressure in the central
aortic pressure wave, effects which cannot be detected with standard
blood pressure monitoring. More than 1,700 SphygmoCor systems are
currently in use worldwide in major medical and research
institutions, physician practices and in various clinical trials with
leading pharmaceutical companies. The company’s technology has been
featured in hundreds of studies published in peer-reviewed medical
journals.
AtCor has operations in the United States, Australia, and Europe.
For more information, visit our website at
* Racial differences in central blood
pressure and vascular function in young men
Generic fosamax pills no prescription Kevin S. Heffernan et al.
Articles in Press. Am J Physiol Heart Circ Physiol.
AtCor Medical
Generic viagra pills no prescription | Buy levitra pills | Buy lexapro pills